A Healthy Volunteer Study To Assess Relative Bioavailability Of Powder-In-Capsule And A Tablet Formulation And The Effect Of Food On The Pharmacokinetics Of The Tablet Formulation

• Drug: PF-05175157
  
  Single 200 mg dose of PF-05175157 administered as powder in capsule (2x100 mg)
• Drug: PF-05175157
  
  Single 200 mg dose of PF-05175157 administered as tablet formulation (2x100 mg)

• Experimental: PF-05175157 PIC in fed state
  
  200 mg single dose of PF-05175157 administered as PIC in the fed state (following a standard high fat meal).
  Intervention: Drug: PF-05175157
• Experimental: PF-05175157 tablet in fed state
  
  200 mg single dose of PF-05175157 administered as tablet formulation in the fed state (following a standard high fat meal).
  Intervention: Drug: PF-05175157
• Experimental: PF-05175157 tablet in fed state (repeat)
  
  200 mg single dose of PF-05175157 administered as tablet formulation in the fed state (following a standard high fat meal).
  Intervention: Drug: PF-05175157
• Experimental: PF-05175157 tablet in fasted state
  
  200 mg single dose of PF-05175157 administered as tablet formulation in the fasted state (following at least a 10 hour fast).
  Intervention: Drug: PF-05175157

Inclusion Criteria:

• Healthy male and/or female subjects between the ages of 18 and 55 years, inclusive
• Women must be of non childbearing potential
• Body Mass Index (BMI) of 25 to 35 kg/m2; and a total body weight >50 kg (110 lbs)

Exclusion Criteria:

• Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing) disease or clinical findings at Screening.
• Active ocular disease including infection, glaucoma, seasonal allergies, dry eye symptoms, optic nerve disease or retinal disease.
• History of habitual smoking in the past 5 years or history or evidence of habitual use of other (non smoked) tobacco or nicotine-containing products within 3 months of Screening or positive cotinine test at Screening or Day 0